Therapeutic Efficacy of Cysteamine Bitartrate in Mouse Model of IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0377; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Delayed-release cysteamine bitartrate was given by oral gavage...Bulk RNA sequencing of kidney and liver tissues demonstrated that cysteamine inhibited multiple inflammatory signaling pathways, including the NF-κB signaling pathway. Conclusion Collectively, cysteamine bitartrate effectively reduces circulating poly-IgA levels and glomerular IgA deposition in different IgA glomerular deposition models, highlighting its potential as a promising therapy for IgAN."
Preclinical • Glomerulonephritis • IgA Nephropathy • Renal Disease
|
|
Xiaohan Yuan; Yihui Zhang; Huixian Li; Li Liu; Qian Jin; Wanhong Lu; Jicheng Lv; Xinfang Xie
|